Cardiac Dimensions® Inc. Announces New Vice President of Research & Development
Mr. Robert Conta joins Senior Management Team
KIRKLAND, Wash.--(BUSINESS WIRE)--Cardiac Dimensions® Inc., is pleased to announce that Mr. Robert Conta has joined the company as Vice President of Research and Development (R&D).
Mr. Conta comes to Cardiac Dimensions from Spiration Inc., a medical device company that manufactures novel interventional pulmonology devices. Prior to Spiration, he ran R&D operations for Spinal Dynamics, Wright Medical Technology, Joint Medical Products Corporation, and Baxter Healthcare Corporation. He also held various R&D positions with the Davis & Geck division of American Cyanamid Company and U.S. Surgical Corporation. Mr. Conta will be responsible for all R&D activities at Cardiac Dimensions, and will spearhead all product improvement and next generation development efforts for the company’s CARILLON™ Mitral Contour System™.
“We are very excited to add Bob to our senior management team. His extensive experience at both large corporations and small start up ventures will be tremendously helpful in leading our R&D efforts through an important phase of our company’s development. Bob’s hiring represents the culmination of a long-term effort to significantly strengthen our senior management team. I am extremely pleased with the breadth and depth of our leadership here at CDI,” commented Rick Stewart, Cardiac Dimension’s President and CEO. “We are exceptionally well positioned with a first class team to execute a well defined plan.”
Approximately 5 million people in theU.S. and over 20 million people worldwide suffer from Heart Failure. Most of these patients also suffer from dilated cardiomyopathy and FMR; the majority of whom are inadequately treated using medical management. While surgical options exist and can be effective in reducing FMR, they are infrequently used due to the burden of the surgery itself, which can be associated with high operative morbidity and mortality rates.
The CARILLON™ Mitral Contour System™ combines a proprietary implantable device and delivery system. The implant consists of a shaping ribbon between distal and proximal anchors. It is delivered percutaneously via jugular vein access under fluoroscopic guidance. The implant is designed to be positioned, adjusted and gently anchored in the coronary sinus/great cardiac vein to reshape the annulus around the mitral valve, thereby reducing mitral regurgitation. Preclinical and early clinical data have suggested both a reduction in mitral regurgitation and improvements in other key parameters including NYHA class, 6 Minute Walk Times and Quality of Life.
Cardiac Dimensions®, Inc., based in Kirkland, Washington, develops and manufactures devices designed for treating heart failure and related conditions.
Contacts
Cardiac Dimensions, Inc.
Tom Douthitt, 425-605-5900
www.cardiacdimensions.com